Picture of Black Diamond Therapeutics logo

BDTX Black Diamond Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+19.46%
3m+82.45%
6m+39.49%
1yr+135.39%
Volume Change (%)
10d/3m+11.18%
Price vs... (%)
52w High-16.2%
50d MA+39.51%
200d MA+75.63%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-62.24%
Return on Equity-70.94%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Black Diamond Therapeutics EPS forecast chart

Profile Summary

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
December 29th, 2014
Public Since
January 30th, 2020
No. of Shareholders
30
No. of Employees
54
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
51,717,849

BDTX Share Price Performance

Upcoming Events for BDTX

Q1 2024 Black Diamond Therapeutics Inc Earnings Release

Black Diamond Therapeutics Inc Annual Shareholders Meeting

Q2 2024 Black Diamond Therapeutics Inc Earnings Release

Similar to BDTX

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ